N-Formyl Peptide Receptor Market Will Generate Record Revenue by 2029

N-Formyl Peptide Receptor Market is anticipated to grow at a significant CAGR during the forecast period. The formyl peptide receptors (FPRs) are G protein-coupled receptors. They transduce chemotactic signals in phagocytes and mediate host-defence as well as inflammatory responses which include cell adhesion, directed migration, granule release and superoxide production. Additionally, N-Formyl peptides are potent immunocyte activators. Once released in the circulation, they induce modulation of vascular tone by cellular mechanisms. The major factor driving the growth of the market include the rising prevalence of diabetes across the globe.

According to the International Diabetes Federation (IDF), in 2021, approximately 537 million adults aged 20-79 years has diabetes globally with 3 in 4 adults with diabetes living in low- and middle-income countries with a mortality rate of 6.7 million people globally. Additionally, the total number of people living with diabetes is anticipated to rise to 643 million by 2030 and 783 million by 2045. Moreover, almost 1 in 2 (240 million) adults living with diabetes are undiagnosed. Hence, the increasing prevalence of diabetes is driving the demand for N-formyl peptide receptor's as genetic or pharmacological inhibition which leads to increased insulin levels and improved glucose tolerance which in turn is driving the growth of the market.

Moreover, based on type, the market is segmented into FPR, FPR2 and FPR3. FPR2 is expected to hold a prominent share in the market owing to its rising application in the treatment of diseases such as cancer, diabetes, among others. They regulate cell function by binding any one of a wide variety of ligands which include N-Formylmethionine-containing oligopeptides such as N-Formylmethionine-leucyl-phenylalanine (FMLP). Some major players in the market include Bristol-Myers Squibb Co., and Merck KGaA, among others.

To Request a Sample of our Report on N-Formyl Peptide Receptor Market: https://www.omrglobal.com/request-sample/n-formyl-peptide-receptor-market

Market Coverage

• The market number available for - 2022-2030

• Base year- 2022

• Forecast period- 2023-2030

Segment Covered-

· By Type

· By Application

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Bristol-Myers Squibb Co., and Merck KGaA, among others.

N-Formyl Peptide Receptor Market Report by Segment

By Type

• FPR1

• FPR2

• FPR3

By Application

• Inflammation

• Diabetes

• Allergies

• Brain Ischemia

• Metastatic Cancer

• Others

A full Report of N-Formyl Peptide Receptor Market is Available @ https://www.omrglobal.com/industry-reports/n-formyl-peptide-receptor-market

N-Formyl Peptide Receptor Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.